Tracers / [18F]AlF-LNC1007

[18F]AlF-LNC1007

Also written as [F-18]AlF-LNC1007

Radionuclide: F-18 t½ 109.77 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 2

Renal cell carcinoma

What it is

Compound class: FAPI-RGD heterodimer (dual FAP/integrin αvβ3-targeting peptide conjugate)
Target / mechanism: Dual-targeting of fibroblast activation protein (FAP) and integrin αvβ3 PMID 40365277
Clinical application: PET/CT imaging of renal cell carcinoma PMID 40365277
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
AllinOne (AiO) Trasis	—	—	36.6 ± 2.4% yes	—	FAPI-RGD precursor (LNC1007) Lannacheng Biotechnology Co., Ltd., Yantai, China	40365277 2025 Theranostics was synthesized using an Allinone module (Trasis, Ans, Belgium) — 36.6 ± 2.4% (n = 4) for the automated process
Manual synthesis	—	—	50 ± 6.8% yes	—	FAPI-RGD precursor (LNC1007) Lannacheng Biotechnology Co., Ltd., Yantai, China	40365277 2025 Theranostics The radiochemical yield (RCY, decay-corrected) was 50 ± 6.8% (n = 8) for the manual method — 50 ± 6.8% (n = 8) for the manual method

Need this precursor?We can point you to suppliers for [18F]AlF-LNC1007, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40365277. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40365277: 'FAPI-RGD precursor (LNC1007)'.